Marksans Pharma’s wholly owned subsidiary -- Relonchem has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK Medicines and Healthcare products Regulatory Agency (MHRA). Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurred.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.
